Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 124 for your search:
Cancer Type/Condition:
Leukemia, acute myeloid (AML), child
Stage/Subtype:
recurrent childhood acute myeloid leukemia
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
MCC-14178
, NCT00361140
2.
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
SCT 0208
, NCT00679536
3.
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
4.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
5.
Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1813.00
, 5666, NCT00075478
6.
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
17 and under
Sponsor:
Other
Protocol IDs:
TRIAL
, TRIAL Relapsed AML 2001/01, NCT00186966
7.
Chemotherapy With or Without Total-Body Irradiation in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI, NHLBI
Protocol IDs:
FHCRC-1992.00
, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
8.
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
2005-0366
, NCT00469144
9.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
10.
Biological Therapy in Treating Patients With Advanced Acute or Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1655.00
, 5430, NCT00052520
11.
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-1803.00
, 5606, NCT00068718
12.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
13.
Iodine I 131 Monoclonal Antibody BC8, Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 to 50
Sponsor:
Other
Protocol IDs:
FHCRC-1809.00
, 5602, NCT00119366
14.
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and under
Sponsor:
Other
Protocol IDs:
ECP RIT
, NCT00179790
15.
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 21
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CLO21800205
, NCT00315705
16.
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
2005-0508
, NCT00402558
17.
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 55
Sponsor:
NCI
Protocol IDs:
MSKCC-06125
, NCT00423514
18.
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2006-1089
, NCT00480987
19.
Busulfan, Etoposide, Intensity-Modulated Radiation Therapy, and Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI
Protocol IDs:
CHNMC-05013
, 05013, NCT00540995
20.
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
2006-0977
, NCT00542971
21.
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
50 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1981.00
, 6508, NCT00555048
22.
Monoclonal Antibody Therapy, Fludarabine, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
23.
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
25 and under
Sponsor:
Other
Protocol IDs:
BMT06407
, H-2006-0297, NCT00582816
24.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
25.
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
UMN-2004LS034
, UMN-2004LS034, MT2004-03, NCT00725062
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
